Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.